The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study

(2016) Jason A. Regules et al.   JOURNAL OF INFECTIOUS DISEASES

Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models

(2016) Melissa A Penny et al.   LANCET

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children

(2016) Ally Olotu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Status of vaccine research and development of vaccines for malaria

(2016) Ashley J. Birkett   VACCINE

RTS,S Malaria Vaccine and Increased Mortality in Girls

(2016) Sabra L. Klein et al.   mBio

Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I–III trials

(2015) Selidji T Agnandji et al.   Future Microbiology

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

(2015) Michael T White et al.   LANCET INFECTIOUS DISEASES

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

(2015) Anthony Ajua et al.   MALARIA JOURNAL

The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease

(2015) Melissa A. Penny et al.   MALARIA JOURNAL

The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015

(2015) S. Bhatt et al.   NATURE

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

(2015) Daniel E. Neafsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

The changing risk of Plasmodium falciparum malaria infection in Africa: 2000–10: a spatial and temporal analysis of transmission intensity

(2014) Abdisalan M Noor et al.   LANCET

Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial

(2014) Rich Umeh et al.   VACCINE

Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites

(2014)   PLOS MEDICINE

Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data

(2013) Philip Bejon et al.   LANCET INFECTIOUS DISEASES

High level of resistance in the mosquito Anopheles gambiae to pyrethroid insecticides and reduced susceptibility to bendiocarb in north-western Tanzania

(2013) Natacha Protopopoff et al.   MALARIA JOURNAL

Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure

(2013) Ally Olotu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antigen-Specific IL-2 Secretion Correlates with NK Cell Responses after Immunization of Tanzanian Children with the RTS,S/AS01 Malaria Vaccine

(2012) A. Horowitz et al.   JOURNAL OF IMMUNOLOGY

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Features of Severe Malaria Associated with Death: A 13-Year Observational Study in The Gambia

(2012) Muminatou Jallow et al.   PLoS One

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E

(2012) Francis M. Ndungu et al.   PLoS One

The RTS,S vaccine candidate for malaria

(2011) Jason A Regules et al.   Expert Review of Vaccines

Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials

(2011) Johan Vekemans et al.   Human vaccines & immunotherapeutics

Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children

(2011) Philip Bejon et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

(2011) Kwaku Poku Asante et al.   LANCET INFECTIOUS DISEASES

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care

(2011) Johan Vekemans et al.   MALARIA JOURNAL

Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children

(2011) Marc Lievens et al.   MALARIA JOURNAL

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine

(2011) Christine Swysen et al.   MALARIA JOURNAL

Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

(2011) Amanda Leach et al.   MALARIA JOURNAL

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Induction of Plasmodium falciparum-Specific CD4+ T Cells and Memory B Cells in Gabonese Children Vaccinated with RTS,S/AS01E and RTS,S/AS02D

(2011) Selidji T. Agnandji et al.   PLoS One

T Cell Responses to the RTS,S/AS01E and RTS,S/AS02D Malaria Candidate Vaccines Administered According to Different Schedules to Ghanaian Children

(2011) Daniel Ansong et al.   PLoS One

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

(2011) Ally Olotu et al.   PLoS One

From the circumsporozoite protein to the RTS,S/AS candidate vaccine

(2010) Joe Cohen et al.   Human vaccines & immunotherapeutics

Evaluation of the Safety and Immunogenicity of the RTS,S/AS01EMalaria Candidate Vaccine When Integrated in the Expanded Program of Immunization

(2010) Selidji T. Agnandji et al.   JOURNAL OF INFECTIOUS DISEASES

Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial

(2010) Arjen M Dondorp et al.   LANCET

Artemisinin resistance—the clock is ticking

(2010) Nicholas J White   LANCET

Safety of the Malaria Vaccine Candidate, RTS,S/AS01E in 5 to 17 Month Old Kenyan and Tanzanian Children

(2010) John Lusingu et al.   PLoS One

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of RTS,S/AS02A and RTS,S/AS01B on Genotypes of P. falciparum in Adults Participating in a Malaria Vaccine Clinical Trial

(2009) John N. Waitumbi et al.   PLoS One

Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

(2009) Seth Owusu-Agyei et al.   PLoS One

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE